Digest Network Come funziona
Network
/
Società
Al
Non verificato

Alentis Therapeutics

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

7 comunicati stampa

Guarda tutti i comunicati
12/11/2025
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Mercato del lavoro
Alentis Strengthens Management Team with Key Appointments
Fonte
Alentis Therapeutics
Emittente
Business Wire
1.00
0
15/10/2025
Alentis Appoints Mark Pruzanski as CEO
Fonte
Alentis Therapeutics
Emittente
Business Wire
1.00
0
09/01/2025
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Alentis Announces Positive Topline Results from Two Studies of Lixudebart (ALE.F02) in Patients with ANCA-RPGN and Advanced Liver Fibrosis
Fonte
Alentis Therapeutics
Emittente
Business Wire
1.00
0
18/11/2024
Scienza
Igiene alimentare
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Oncologia
Industria
Alentis Receives FDA Fast Track Designation for ALE.P02 for the Treatment of CLDN1+ Squamous Solid Tumors
Fonte
Alentis Therapeutics
Emittente
Business Wire
1.00
0
12/11/2024
Industria
Oncologia
Salute
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
Alentis Therapeutics Raises $181.4 Million in an Oversubscribed Series D Financing to Advance the Clinical Development of Anti-Claudin-1 ADCs in Solid Tumors
Fonte
Alentis Therapeutics
Emittente
Business Wire
1.00
0
02/10/2024
Industria
Oncologia
Salute
Igiene alimentare
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
Alentis Therapeutics Receives FDA IND Clearance for ALE.P02, a Novel CLDN1-ADC for the Treatment of Squamous Cancers
Fonte
Alentis Therapeutics
Emittente
Business Wire
1.00
0
03/09/2024
Alentis Appoints Jonathan Freve CFO
Fonte
Alentis Therapeutics
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0